Valuation: Nipro Corporation

Market Cap 26TCr 164.77Cr 142.32Cr 133.73Cr 121.62Cr 228.66Cr 16TCr 232.43Cr 1.57TCr 612.67Cr 7.89TCr 618.65Cr 605.22Cr P/E 2027 *
17.2x
P/E 2028 * 13.3x
Enterprise Value 77TCr 484.72Cr 418.66Cr 393.41Cr 357.78Cr 672.66Cr 46TCr 683.75Cr 4.61TCr 1.8TCr 23TCr 1.82TCr 1.78TCr EV / Sales 2027 *
1.1x
EV / Sales 2028 * 1.03x
Free-Float
84.43%
Yield 2027 *
2.27%
Yield 2028 * 2.85%
31/07 Nipro Corporation Receives Fda 510(K) Clearance for Elisio-Hx Dialyzer and Introduces Hds to the United States CI
29/07 Vat Holding AG agreed to acquire 100% stake in Atonarp Inc. from Nipro Corporation for CHF 110 million. CI
14/07 Jefferies Adjusts Nipro's Price Target to 1,700 Yen From 1,500 Yen, Keeps at Hold MT
12/05 Nipro Corporation Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2026 and Fiscal Year Ending March 31, 2027 CI
12/05 Nipro Corporation Announces Year-End Dividend for Fiscal Year Ended March 31, 2026, Payable on June 10, 2026; Provides Second Quarter-End and Year-End Dividend Guidance for Fiscal Year Ending March 31, 2027 CI
01/05 Jefferies Adjusts Nipro's Price Target to 1,500 Yen From 1,300 Yen, Keeps at Hold MT
11/03 Nipro Fixes Record Date for Fiscal 2026 Year-End Dividend MT
09/02 Nipro Corporation Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
24/12 Nipro Corporation Announces Establishment of Wholly Owned Subsidiary in Singapore CI
10/11 Nipro Corporation Announces Dividend for the Second Quarter End of Fiscal Year Ending March 31, 2026, Payable on December 10, 2025 CI
10/25/10 Samsung Bioepis Partners With Nipro to Commercialize Biosimilars in Japan MT
09/25/09 Samsung Bioepis Co., Ltd. Enters into A Strategic Partnership with NIPRO Corporation for Commercialization of Multiple Biosimilars in Japan CI
13/25/13 Jefferies Adjusts Nipro's Price Target to 1,300 Yen from 1,400 Yen, Keeps at Hold MT
1 day+2.79%
Current month+21.02%
Current year+21.02%
3 years 8.23
Extreme 8.23
9.96
5 years 8.23
Extreme 8.23
9.96
10 years 8.23
Extreme 8.23
9.96
Manager TitleAgeSince
Director of Finance/CFO 57 01/06/2025
President 58 01/06/2025
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 81 26/06/2025
Director/Board Member 53 01/06/2009
Director/Board Member 58 01/06/2009
Change 5-day change 1-year change 3-year change Capi.($)
+2.79%-.--% - - 163.49Cr
-0.02%+3.05%-14.03%+5.64% 19TCr
+0.76%+6.23%-1.77%+9.37% 12TCr
+1.43%-3.44%+7.83%+67.49% 5.92TCr
+0.32%+4.59%+34.37%+62.62% 5.57TCr
+0.79%+3.57%-6.41%-35.04% 4.96TCr
-1.89%+8.11%+12.24%-19.64% 3.45TCr
+0.45%+3.56% - - 3.12TCr
+0.94%+0.24%+41.91%-11.48% 2.44TCr
+1.98%+15.59%-4.40%+22.62% 2.43TCr
Average +0.72%+3.97%+8.72%+12.70% 6.53TCr
Weighted average by Cap. +0.30%+3.47%+0.89%+13.50%

Financials

2027 *2028 *
Net sales 70TCr 440.31Cr 380.3Cr 357.36Cr 325Cr 611.03Cr 42TCr 621.1Cr 4.19TCr 1.64TCr 21TCr 1.65TCr 1.62TCr 73TCr 458.06Cr 395.63Cr 371.77Cr 338.1Cr 635.66Cr 44TCr 646.14Cr 4.36TCr 1.7TCr 22TCr 1.72TCr 1.68TCr
Net income 1.54TCr 9.67Cr 8.36Cr 7.85Cr 7.14Cr 13Cr 925.02Cr 14Cr 92Cr 36Cr 463.22Cr 36Cr 36Cr 2TCr 13Cr 11Cr 10Cr 9.26Cr 17Cr 1.2TCr 18Cr 119.25Cr 47Cr 600.44Cr 47Cr 46Cr
Net Debt 51TCr 319.95Cr 276.34Cr 259.67Cr 236.16Cr 444Cr 31TCr 451.32Cr 3.04TCr 1.19TCr 15TCr 1.2TCr 1.18TCr 49TCr 307.53Cr 265.61Cr 249.59Cr 226.99Cr 426.76Cr 29TCr 433.8Cr 2.92TCr 1.14TCr 15TCr 1.15TCr 1.13TCr
Logo Nipro Corporation
Nipro Corp is a Japan-based company mainly engaged in the medical, pharmaceutical, and pharma packaging businesses. It has three segments. The Medical segment consists of the domestic business division and the international business division. The domestic business division sells medical devices related to injections and infusions, artificial organs, high-performance medicines, and dialysis. The international business division, centered on the head office, has medical device manufacturing and sales bases overseas for regional expansion, selling medical devices related to injections and infusions, artificial organs, and diabetes. The Pharmaceutical segment sells pharmaceuticals related to kit preparation containers on a contract basis from pharmaceutical companies. The Pharma Packaging segment sells medical glass products such as glass tubes and ampoules, thermos flasks, and kit preparation containers in Japan.
Employees
38,593
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
1,595.00JPY
Average target price
1,986.00JPY
Spread / Average Target
+24.51%

Quarterly revenue - Rate of surprise